The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation
Cancer · 2025
DOI: 10.1002/cncr.35666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Bryson W Katona und 22 weiteren Autor:innen. Beteiligte Einrichtung: Basser Center for BRCA and Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsyl…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Peter Gilgan Foundation, CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
The lifetime risk of pancreatic cancer in women with a germline mutation in BRCA1 and BRCA2 is not well established. In an international prospective cohort of female carriers of BRCA1 and BRCA2 mutations, the cumulative incidence of pancreatic cancer from age 40 until 80 years was estimated.
Methods
A total of 8295 women with a BRCA1 or BRCA2 mutation were followed for new cases of pancreatic cancer. Subjects were followed from the date of baseline questionnaire or age 40 years (whichever came last) until a new diagnosis of pancreatic cancer, death from another cause, or date of last follow‐up.
Results
Thirty‐four incident pancreatic cancer cases were identified in the cohort. The annual risk of pancreatic cancer between age 40 and 80 years was 0.04% for BRCA1 carriers and 0.09% for BRCA2 carriers. Via the Kaplan–Meier method, the cumulative incidence from age 40 to 80 years was 2.2% (95% CI, 1.1%–4.3%) for BRCA1 carriers and 2.7% (95% CI, 1.3%–5.4%) for BRCA2 carriers. Only two of the 34 cases reported a first‐degree relative with pancreatic cancer (hazard ratio, 4.75; 95% CI, 1.13–19.9; p = .03). Risk factors for pancreatic cancer included alcohol intake and a history of diabetes. The 5‐year survival rate for the 34 cases was 8.8%.
Conclusions
The lifetime risk of pancreatic cancer is approximately 2% in women with a BRCA1 mutation and 3% for women with a BRCA2 mutation. The poor survival in hereditary pancreatic cancer underscores the need for novel antitumoral strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Basser Center for BRCA and Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
- Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
- Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada.
ORCID-Profile: Amber Aeilts, Christian F Singer, Olufunmilayo Olopade, Joanne Kotsopoulos, Steven A Narod
Förderung
- Peter Gilgan Foundation
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Katona, B. W., Lubinski, J., Pal, T., Huzarski, T., Foulkes, W. D., Moller, P., Eisen, A., Randall Armel, S., Neuhausen, S. L., Raj, R., Aeilts, A., Singer, C. F., Bordeleau, L., Karlan, B., Olopade, O., Tung, N., Zakalik, D., Kotsopoulos, J., Fruscio, R., …, & Hereditary Breast Cancer Clinical Study Group (2025). The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. Cancer. https://doi.org/10.1002/cncr.35666
Vancouver
Katona BW, Lubinski J, Pal T, Huzarski T, Foulkes WD, Moller P, et al. The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. Cancer. 2025. doi:10.1002/cncr.35666
BibTeX
@article{Katona2025,
author = {Katona, Bryson W and Lubinski, Jan and Pal, Tuya and Huzarski, Tomasz and Foulkes, William D and Moller, Pal and Eisen, Andrea and Randall Armel, Susan and Neuhausen, Susan L and Raj, Rebecca and Aeilts, Amber and Singer, Christian F and Bordeleau, Louise and Karlan, Beth and Olopade, Olufunmilayo and Tung, Nadine and Zakalik, Dana and Kotsopoulos, Joanne and Fruscio, Robert and Eng, Charis and Sun, Ping and Narod, Steven A and Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group},
title = {The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35666}
}
EUVIMED